J&J's Janssen Gets FDA OK of Twice-Yearly Invega for Adults With Schizophrenia

By Colin Kellaher

Johnson & Johnson's Janssen Pharmaceutical Cos. unit on Wednesday said the U.S. Food and Drug Administration approved a six-month version of its antipsychotic Invega.

The drug maker said Invega Hafyera is the first FDA-approved twice-yearly injectable for the treatment of schizophrenia in adults.

Janssen said patients must first be treated with its Invega Sustenna one-month drug for at least four months or its Invega Trinza three-month dose at least once before switching to the new six-month Invega Hafyera.

Write to Colin Kellaher at [e-mail]

(END) Dow Jones Newswires

09-01-21 0845ET